Alto Neuroscience ANRO Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's operating lease right-of-use asset amortization?
- Alto Neuroscience (ANRO) reported operating lease right-of-use asset amortization of $200K in Q1 2026.
- How has Alto Neuroscience's operating lease right-of-use asset amortization changed year-over-year?
- Alto Neuroscience's operating lease right-of-use asset amortization increased by 5.3% year-over-year, from $190K to $200K.
- What is the long-term trend for Alto Neuroscience's operating lease right-of-use asset amortization?
- Over 2 years (2023 to 2025), Alto Neuroscience's operating lease right-of-use asset amortization has grown at a 66.3% compound annual growth rate (CAGR), from $280K to $774K.